Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Bittner

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
Plos Genetics|May 3, 2011
DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophiesWolfgang M Schmidt, Mohammed H Uddin, Sandra Dysek, et al.
European Journal of Human Genetics : EJHG|May 30, 2013
Novel form of X-linked nonsyndromic hearing loss with cochlear malformation caused by a mutation in the type IV collagen gene COL4A6Simone Rost, Elisa Bach, Cordula Neuner, et al.
Neurology|October 7, 2018
Evidence of mild founder <i>LMOD3</i> mutations causing nemaline myopathy 10 in Germany and AustriaUlrich A Schatz, Simone Weiss, Stephan Wenninger, et al.
Hypertension (Dallas, Tex. : 1979)|July 1, 1995
Effects of SC-56525, a potent, orally active renin inhibitor, in salt-depleted and renal hypertensive dogsE G McMahon, P C Yang, M A Babler, et al.
Biochemical and Biophysical Research Communications|April 14, 1989
A new class of orally active glycol renin inhibitors containing phenyllactic acid at P3G J Hanson, J S Baran, H S Lowrie, et al.
Retina (Philadelphia, Pa.)|December 8, 2017
IMAGING OF VITELLIFORM MACULAR LESIONS USING POLARIZATION-SENSITIVE OPTICAL COHERENCE TOMOGRAPHYGábor G Deák, Wolfgang M Schmidt, Reginald E Bittner, et al.
Journal of Cardiovascular Pharmacology|October 1, 1993
Pharmacology of SC-52458, an orally active, nonpeptide angiotensin AT1 receptor antagonistG M Olins, V M Corpus, S T Chen, et al.
Neuropediatrics|January 5, 2023
Treatment of Mitochondrial Phenylalanyl-tRNa-Synthetase Deficiency (FARS2) with Oral PhenylalanineSusanne L Oswald, Katja Steinbrücker, Melanie T Achleitner, et al.
European Journal of Medical Genetics|December 22, 2010
SNP-array based whole genome homozygosity mapping: a quick and powerful tool to achieve an accurate diagnosis in LGMD2 patientsLea Papić, Dirk Fischer, Slave Trajanoski, et al.
Neuromuscular Disorders : NMD|January 24, 2007
A third of LGMD2A biopsies have normal calpain 3 proteolytic activity as determined by an in vitro assayAstrid Milic, Nathalie Daniele, Hanns Lochmüller, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Plos Genetics|May 3, 2011
DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophiesWolfgang M Schmidt, Mohammed H Uddin, Sandra Dysek, et al.
European Journal of Human Genetics : EJHG|May 30, 2013
Novel form of X-linked nonsyndromic hearing loss with cochlear malformation caused by a mutation in the type IV collagen gene COL4A6Simone Rost, Elisa Bach, Cordula Neuner, et al.
Neurology|October 7, 2018
Evidence of mild founder <i>LMOD3</i> mutations causing nemaline myopathy 10 in Germany and AustriaUlrich A Schatz, Simone Weiss, Stephan Wenninger, et al.
Hypertension (Dallas, Tex. : 1979)|July 1, 1995
Effects of SC-56525, a potent, orally active renin inhibitor, in salt-depleted and renal hypertensive dogsE G McMahon, P C Yang, M A Babler, et al.
Biochemical and Biophysical Research Communications|April 14, 1989
A new class of orally active glycol renin inhibitors containing phenyllactic acid at P3G J Hanson, J S Baran, H S Lowrie, et al.
Retina (Philadelphia, Pa.)|December 8, 2017
IMAGING OF VITELLIFORM MACULAR LESIONS USING POLARIZATION-SENSITIVE OPTICAL COHERENCE TOMOGRAPHYGábor G Deák, Wolfgang M Schmidt, Reginald E Bittner, et al.
Journal of Cardiovascular Pharmacology|October 1, 1993
Pharmacology of SC-52458, an orally active, nonpeptide angiotensin AT1 receptor antagonistG M Olins, V M Corpus, S T Chen, et al.
Neuropediatrics|January 5, 2023
Treatment of Mitochondrial Phenylalanyl-tRNa-Synthetase Deficiency (FARS2) with Oral PhenylalanineSusanne L Oswald, Katja Steinbrücker, Melanie T Achleitner, et al.
European Journal of Medical Genetics|December 22, 2010
SNP-array based whole genome homozygosity mapping: a quick and powerful tool to achieve an accurate diagnosis in LGMD2 patientsLea Papić, Dirk Fischer, Slave Trajanoski, et al.
Neuromuscular Disorders : NMD|January 24, 2007
A third of LGMD2A biopsies have normal calpain 3 proteolytic activity as determined by an in vitro assayAstrid Milic, Nathalie Daniele, Hanns Lochmüller, et al.
Pageof 10